Klin Farmakol Farm. 2005;19(3):152-154

The impact of statins in geriatrics

prof. MUDr. Vladimír Bláha CSc
Klinika gerontologická a metabolická, FN Hradec Králové

The clinical efficacy and safety of statin therapy have been well established from a series of large-scale, randomized controlled trials. These trials, however, have predominantly recruited patients under the age of 70 years. As a consequence, the use of statins in older patients has remained controversial. The results of the first trial evaluating exclusively elderly patients – the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) – have contributed enormously to our understanding of the use of statins in the elderly. These findings, together with the results from the large elderly cohort within the Heart Protection Study and smaller elderly subgroups within other major statin trials, have forced us to re-evaluate any systematic exclusion of elderly patients from the indication for statin therapy.

Keywords: Key words: statin therapy, elderly, aging, atherosclerosis.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bláha V. The impact of statins in geriatrics. Klin Farmakol Farm. 2005;19(3):152-154.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389. Go to original source...
    2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng J Med 1995; 333: 1301-1307. Go to original source... Go to PubMed...
    3. Sacks FM, Pfeffer MA, Moyé LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996; 335: 1001-1009. Go to original source... Go to PubMed...
    4. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of cholesterol levels. N Eng J Med 1998; 339: 1349-1357. Go to original source... Go to PubMed...
    5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TEXCAPS Research Group. JAMA 1998; 279: 1615-1622. Go to original source... Go to PubMed...
    6. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630. Go to original source... Go to PubMed...
    7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22. Go to original source... Go to PubMed...
    8. Bruckert E, Li?vre M, Giral P, et al. Short-term efficacy and safety of extended release fluvastatin in a large cohort of elderly patients. Am J Geriatric Cardiol 2003; 12: 225-231. Go to original source... Go to PubMed...
    9. Aronow WS. Effect of statins on mortality and cardiovascular events in elderly high-risk persons. J Am Geriatr Soc 2003; 51: 717-718. Go to original source... Go to PubMed...
    10. Farmer JA, Gotto AM. The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol 2003; 92 (Suppl): 3i-9i. Go to original source... Go to PubMed...
    11. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Eur Heart J 2001; 22: 554-572. Go to original source... Go to PubMed...
    12. Reid FD, Cook DG, Whincup PH. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 2002; 88: 15-19. Go to original source... Go to PubMed...
    13. Whincup PH, Emberson JR, Lennon L, et al. Low prevalence of lipid lowering heart drug use in older men with established coronary heart disease. Heart 2002; 88: 22-29. Go to original source... Go to PubMed...
    14. Williams D, Bennett K, Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Brit J Clin Pharmacol 2003; 55: 604-608. Go to original source... Go to PubMed...
    15. DeWilde S, Carey IM, Bremner SA, et al. Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart 2003; 89: 417-421. Go to original source... Go to PubMed...
    16. Lalouschek W, Lang W, Greisenegger S, Mullner M. Determination of lipid profiles and use of statins in patients with ischemic stroke or transient ischemic attack. Stroke 2003; 34: 105-110. Go to original source... Go to PubMed...
    17. Levy AR, O'Brien BJ, McMullen E, et al. Rapid increase in statins newly dispensed to Ontario seniors between 1994-2000. Can J Cardiol 2003; 19: 665-669.
    18. Mungall MMB, Gaw A, Shepherd J. Statin therapy in the elderly: does it make good clinical and economic sense? Drugs Aging 2003; 20: 263-275. Go to original source... Go to PubMed...
    19. Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999; 159: 593-600. Go to original source... Go to PubMed...
    20. Avorn J, Benner J, Ford I, et al. Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial. Control Clin Trials 2002; 23: 757-773. Go to original source... Go to PubMed...
    21. Strandberg TE, Pitkala K, Berglind S, et al. Possibilities of multifactorial cardiovascular disease prevention in patients aged 75 and older: a randomised controlled trial: Drugs and Evidence Based Medicine in the Elderly (DEBATE). Eur Heart J 2003; 24: 1216-1222. Go to original source... Go to PubMed...
    22. Gaw A, Robertson M, Ford I, PROSPER Study Group. Framingham risk equations underestimate risk in older subjects. Circulation 2003; 108 (Suppl): IV-721.
    23. Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003; 92: 711-712. Go to original source... Go to PubMed...
    24. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946-1949. Go to original source... Go to PubMed...
    25. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus. Circulation 2001; 103: 357-362. Go to original source... Go to PubMed...
    26. McGwin G, Owsley C, Curcio CA, Crain RJ. The association between statin use and age related maculopathy. Br J Ophthalmol 2003; 87: 1121-1125. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.